N or years (%) | Cohort 1 | Cohort 2 |
---|---|---|
Number of patients | 216 | 210 |
Number of events* | 57 | 51 |
Median follow-up,† years | 6.0 | 10.9 |
Time at risk, years | 1139 | 1939 |
Age median, years (range) | 64 (31–81) | 47 (30–57) |
Nodal status | ||
Negative | 72 (33) | 210 (100) |
Positive | 144 (67) | 0 (0) |
Missing | 0 | 0 |
ER status | ||
Positive | 146 (69) | 140 (67) |
Negative | 66 (31) | 70 (33) |
Missing | 4 | 0 |
PR status | ||
Positive | 105 (50) | 153 (73) |
Negative | 107 (50) | 57 (27) |
Missing | 4 | 0 |
HER2 status | ||
Positive | 36 (17) | 22 (11) |
Negative | 179 (83) | 175 (89) |
Missing | 1 | 13 |
Tumour size (mm) | ||
≤20 | 50 (23) | 158 (75) |
>20 | 166 (77) | 52 (25) |
Missing | 0 | 0 |
Histological grade | ||
1 | 3 (2) | 65 (31) |
2 | 99 (64) | 76 (37) |
3 | 53 (34) | 67 (32) |
Missing | 61 | 2 |
Ki67 (%) | ||
≤20 | 62 (78) | 128 (68) |
>20 | 17 (22) | 61 (32) |
Missing | 137 | 21 |
*Distant metastasis or breast cancer death.
†Median follow-up (years) for the end point DDFS for patients alive and free from event at end of follow-up.
DDFS, distant disease-free survival; ER, oestrogen receptor; HER2, human epidermal growth factor receptor 2; PR, progesterone receptor.